Effect of long-term treatment with circulating thymic factor on murine lupus.
Mice from three different strains (NZB, B/W, and Swan) which spontaneously develop a lupus-like disease and show a premature decline of their secretion of the circulating thymic factor, Facteur Thymique Sérique (FTS), were treated repeatedly with FTS and followed for the evolution of their autoimmune disease. The autoimmune sialoadenoitis (Sjögren's syndrome) appearing in NZB and B/W mice, evaluated here by a scintigraphic method, was completely prevented or even cured by FTS treatment. The increase in anti-erythrocyte autoantibody production was transiently delayed in aged NZB mice. Conversely, antiDNA antibody production either remained unaffected or was accelerated (in B/W mice) by FTS treatment. These results demonstrate that the restoration of the failing thymic secretion does influence autoantibody production, in a manner depending primarily on the autoantigen eliciting the autoimmune response. However, caution is urged in the application of this approach to human lupus without further studies.
D000367:Age Factors; D000818:Animals; D001323:Autoantibodies / Q000096:biosynthesis; D001327:Autoimmune Diseases / Q000188:drug therapy*; D004247:DNA / Q000276:immunology; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006728:Hormones / Q000008:administration & dosage; D051379:Mice; D008810:Mice, Inbred C57BL; D008814:Mice, Inbred NZB; D012859:Sjogren's Syndrome / Q000188:drug therapy / Q000517:prevention & control*; D013935:Thymic Factor, Circulating / Q000008:administration & dosage* / Q000627:therapeutic use; D013951:Thymus Hormones / Q000008:administration & dosage*; D013997:Time Factors
D001323:Autoantibodies; D006728:Hormones; D013951:Thymus Hormones; D004247:DNA; D013935:Thymic Factor, Circulating